CD86 and lymphoma: Therefore, we analyzed matched tumor biopsies derived from seven patients with aggressive B-NHL (six DLBCL, one follicular lymphoma after transformation into an aggressive lymphoma [tFL]) and one follicular lymphoma (FL) patient before and after CAR T cell treatment by immunohistochemistry analyses for the expression of both ligands, CD80 and CD86.